Employees: 1,097
Size Sanofi India (SANOFI.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $797M, the 675th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,232 on 18 Nov 2026.
Performance Over six months the shares was unchanged, against -8.3% for the median peer and +3.8% for the India market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue fell 5.7% over the last twelve months (peer median +2.8%); the operating margin is 26.3% (peer median 5.0%).
Valuation It trades at 19.6× forward earnings against a peer median of 10.8× (4th most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is -9%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 32.7 points above its cost of capital (15.2% WACC).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹18.2B | ₹18.4B | ₹20.1B | ₹19.9B | ₹27.6B |
| Revenue growth | — | -9% | +1% | -28% | — |
| Gross profit | ₹7.14B | ₹6.82B | ₹7.09B | ₹6.89B | ₹10.4B |
| EBITDA | ₹5.15B | ₹5.08B | ₹5.01B | ₹5.02B | ₹7.18B |
| Net income | ₹3.65B | ₹3.27B | ₹4.13B | ₹6.03B | ₹6.21B |
| Free cash flow | n/a | ₹4.25B | ₹4.42B | ₹2.44B | ₹4.34B |
| Capital expenditure | n/a | ₹257M | ₹364M | ₹343M | ₹222M |
| Total debt | n/a | ₹178M | ₹193M | ₹190M | ₹236M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SANOFI.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.2% | -3.8% | 2nd highest of 19 |
| 6-month return | 0.0% | -8.3% | 6th highest of 19 |
| Distance from 52-week high | -30.9% | -34.8% | 8th highest of 19 |
| Revenue growth (TTM) | -5.7% | +2.8% | 6th lowest of 19 |
| Operating margin | 26.3% | 5.0% | 2nd highest of 19 |
| Forward P/E | 19.6× | 10.8× | 4th most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 16.3% | 4.6% | 3rd most demanding of 10 |
| Growth delivered (Del g) | -8.7% | +17.7% | 2nd lowest of 10 |
| Hurdle (Req g minus delivered) | +25.0 pp | -11.1 pp | 2nd most demanding of 10 |
| ROIC minus cost of capital | +32.7 pp | -2.3 pp | 2nd highest of 18 |
| EV / EBITDA | 14.5× | 8.7× | 2nd most expensive of 7 |
| Net debt / EBITDA | -0.5× | 0.3× | 4th least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 19.6× | 16.3% | -8.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 10.8× | 1.5% | +22.1% |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 24.3× | 13.9% | +27.7% |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 42.2× | 6.6% | +17.7% |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 3.5× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | n/a | n/a | n/a |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 3.7× | -2.6% | +20.3% |
| Jinghua Pharmaceutical 002349.SZ | China | $785M | -8% | +2% | 20% | n/a | -2.5% | +2.6% |
| Ardelyx ARDX | United States | $784M | -50% | +18% | -8% | 252.9× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 10.4× | 4.6% | +22.5% |
| Zhejiang Int'l 000411.SZ | China | $783M | -21% | +3% | 3% | n/a | n/a | n/a |
| Sichuan Neautus Traditional Chinese 2206.HK | Hong Kong | $779M | n/a | +7% | 8% | n/a | n/a | n/a |
| Bliss GVS Pharma BLISSGVS.NS | India | $777M | +141% | +25% | 18% | n/a | 33.9% | +10.1% |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $771M | -7% | -13% | 4% | n/a | -3.8% | -0.8% |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $766M | -22% | -46% | -147% | n/a | n/a | n/a |